Chimerix, Inc. Appoints Heather Knight-Trent as Vice President of Regulatory Affairs
September 12, 2017 at 12:00 pm
Share
Chimerix, Inc. announced the appointment of Heather Knight-Trent, PharmD, as vice president of regulatory affairs. Dr. Knight-Trent brings more than 15 years of pharmaceutical regulatory experience to the company and will be responsible for managing all U.S. and global regulatory matters for the company, including strategy, filings and interactions with regulatory authorities. Dr. Knight-Trent was previously executive director of regulatory affairs at Hurley Consulting Associates, where she was responsible for regulatory strategy and implementation for multiple clients. She was previously at Bristol Myers Squibb for ten years in roles both in the U.S. and Europe, most recently as the director of global regulatory, safety and biometrics business operations. In this role Dr. Knight-Trent supported the vice presidents of global regulatory strategy for all therapeutic areas on resourcing, budget, group capabilities and continuous improvement projects.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.